This recombinant monoclonal antibody is developed as a research-grade biosimilar to maridebart, targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR). GIPR is a G protein-coupled receptor primarily expressed in pancreatic beta cells, adipose tissue, and bone, where it mediates the effects of the incretin hormone GIP. Upon activation, GIPR stimulates insulin secretion in a glucose-dependent manner, influences lipid metabolism, and plays a role in energy homeostasis. Dysregulation of GIPR signaling has been implicated in metabolic disorders including type 2 diabetes and obesity, making it an important therapeutic target for metabolic disease research.
Maridebart is a clinical-stage therapeutic antibody designed as a GIPR antagonist, being investigated for its potential in treating obesity and metabolic syndrome by modulating incretin receptor pathways. This biosimilar antibody provides researchers with a valuable tool for investigating GIPR biology, studying incretin-based mechanisms, exploring metabolic pathway interactions, and supporting preclinical studies in diabetes and obesity research. It enables detailed examination of GIPR function in various experimental models and cellular systems.
Email: support@cusabio.com
Distributors Worldwide